je.st
news
Tag: tumor
Knowledge-Based Software Can Significantly Expedite Creation of High-Quality Radiotherapy Treatment Plans for Precise Tumor Targeting
2015-10-26 11:31:11| Industrial Newsroom - All News for Today
Researchers confirm that RapidPlan technology can dramatically improve the speed and quality of cancer care PALO ALTO, Calif. - Studies presented earlier this week at the 2015 annual meeting of the American Society for Radiation Oncology (ASTRO) confirmed that knowledge-based treatment planning software can...
Tags: software
plans
treatment
creation
Sprint Bioscience Enters into Collaboration with Bayer Healthcare on Tumor Metabolism Program
2015-07-28 09:16:55| Appliances - Topix.net
Sprint Bioscience AB and Bayer HealthCare have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer.
Tags: program
collaboration
healthcare
metabolism
Nintendo President Satoru Iwata dies of tumor
2015-07-13 05:09:51| Electronics - Topix.net
In this July 15, 2008 file photo, Satoru Iwata, President and CEO of Nintendo Co. Ltd., speaks at a news conference where Nintendo unveiled an enhancement for its Wii Remote controller and new games at the E3 Media and Business Summit in Los Angeles.
Tags: president
dies
nintendo
tumor
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
2015-06-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282orClaire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: add
data
types
presented
ASCO '15: Celldex Immunotherapy Maintains Survival Benefit for Recurrent Brain Tumor Patients
2015-05-31 15:23:06| Logistics - Topix.net
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 9+ You may proceed to the site by clicking here , however some pages might not work correctly.
Tags: benefit
patients
brain
survival